Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents

• Published in: Molecular genetics and metabolism Vol. 129; no. 4; pp. 278 - 285
• Main Authors: Thibault, Nathan, Ibrahim, Jennifer, Peterschmitt, M. Judith, Puga, Ana Cristina, Ross, Leorah, Vu, Lucie, Xue, Yong, Turpault, Sandrine
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2020
• Subjects: Acid-reducing agents; Adolescent; Adult; Contraceptives, Oral - administration & dosage; Contraceptives, Oral - adverse effects; Contraceptives, Oral - pharmacokinetics; Cross-Over Studies; CYP2D6 metabolism; Digoxin; Digoxin - administration & dosage; Digoxin - adverse effects; Digoxin - pharmacokinetics; Drug Interactions; Eliglustat; Female; Humans; Male; Metoprolol; Metoprolol - administration & dosage; Metoprolol - adverse effects; Metoprolol - pharmacokinetics; Middle Aged; Oral contraceptives; Pharmacokinetics; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - adverse effects; Pyrrolidines - administration & dosage; Young Adult; CYP2D6 metabolism; Metoprolol; Digoxin; Acid-reducing agents; Drug interactions; Eliglustat; Pharmacokinetics; Oral contraceptives

Eliglustat is an oral substrate reduction therapy indicated for patients with Gaucher disease type 1. Based on in vitro data, clinical trials were conducted to assess the potential for drug-drug interactions between eliglustat and digoxin (P-glycoprotein substrate), metoprolol (sensitive CYP2D6 subs...